HLS Therapeutics Inc (FRA:74D)
€ 2.38 0.08 (3.48%) Market Cap: 78.06 Mil Enterprise Value: 126.68 Mil PE Ratio: 0 PB Ratio: 1.08 GF Score: 66/100

Q2 2024 HLS Therapeutics Inc Earnings Call Transcript

Aug 08, 2024 / 12:30PM GMT
Release Date Price: €1.97 (+1.03%)
Operator

Good morning, and welcome to the Q2 fiscal 2024 financial results conference call for HLS Therapeutics. On this morning's call, we have Craig Millian, Chief Executive Officer, and John Hanna, Interim Chief Financial Officer. (Operator Instructions)

HLS issued a news release announcing its financial results for the three and six months ended June 30, 2024. This news release, along with the company's MD&A and financial statements, are available on HLS website and on SEDAR+.

Please note that slides accompanying today's call can be viewed via webcast, a link to which is available in the company's earnings press release and at its website on the events page, certain matters discussed in today's conference call assurance that may be given to questions could constitute forward-looking statements.

Actual results could differ materially from those anticipated risk factors that could affect results are detailed in the Company's annual information form, which has been filed on SEDAR+ at www.sedarplus.com. During this

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot